Estimating population average treatment effects from experiments with noncompliance

Journal:	*Journal of Causal Inference*
Manuscript ID	Draft
Manuscript Type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Ottoboni, Kellie; University of California Berkeley, Statistics Poulos, Jason; University of California Berkeley, Political Science
Classifications:	causal inference
Keywords:	noncompliance, randomized controlled trials, external validity, ensemble methods, population

Revision Memo:
"Estimating population average treatment effects from experiments with noncompliance" (DGJCI.2018.0011)

1 Reviewer: 1 (R1)

1.1 Expand set of simulations

Following R1's excellent suggestion, we expand the set of simulations to follow more of an experimental design, by varying the parameters that determine the degree of confounding with sample selection, confounding with treatment assignment, and confounding with compliance. In addition, we made the following changes to the simulations:

- Compare the PATT and PATT-C estimators against the SATE, which is just the ITT effect scaled by the compliance rate, since the SATE is a more appropriate benchmark
- Use gradient boosting to predict compliance rate in the RCT and to predict the potential outcomes of observed and predicted RCT compliers
- Vary the e_k, $k = \{1...6\}$ parameters along a grid of five standard normal deviates

In the new simulations, we find that the estimation error of PATT-C is invariant to increases in the compliance rate. In comparison, SATE performs worse when the compliance rate is low, and is also considerably more variable than both of the population estimators due to the fact that SATE is unable to account for differences in pretreatment covariates between the RCT sample and target population.

1.2 Presentation

1.2.1 Assumptions

Following R1's suggestion, we have moved Assumptions 1 – 5 from the Appendix into the main text.

1.2.2 Consistency for index i

R1 points out that the subject-level index i is inconsistently used in the original manuscript. The revised manuscript ensures that all subject-level quantities are indexed with i.

1.2.3 Define SATT

In the revised manuscript, we compare the PATT and PATT-C estimators against the SATE, which is just the ITT effect scaled by the compliance rate, since the SATE is a more common estimator.

1.2.4 NHIS sample design

R1 points out that the complex sample design of the NHIS was ignored in the application. Footnote 8 notes this as a limitation and also references a National Center for Health Statistics report on the NHIS sampling design. The revised manuscript also properly cites NHIS as a data source.

1.2.5 Interpretation of results

R1 suggests providing more context for interpreting whether the subgroup analyses presented in Section 5.4 are reasonable. We expand Section 5.4 in the revised manuscript to compare our sample subgroup estimates with those published in the online appendices of (Taubman et al. 2014) and Kowalski (2016). These studies do not perform subgroup analyses for the broader population. Similar to our sample estimates, these studies find considerable treatment effect heterogeneity in terms of gender, age, smoking status, and pre-lottery welfare participation.

In addition, R1 points out that in the Discussion of the original manuscript, the direction of the PATT estimates on ER and outpatient visits are incorrectly described. The revision removes this description as it is not relevant to the discussion on subgroup analyses.

2 Reviewer: 2 (R2)

2.1 Identifying assumptions

2.1.1 Conditioning on D_i

R2 suggests framing the ignorability Assumptions 3 and 4 on D_i rather than T_i and C_i to be more consistent with the framing of Hartman et al. (2015) and to ensure that treatment means the same thing in both the experiment and the population. The reason we decided to frame the ignorability assumptions conditional on T_i and C_i is to distinguish between noncompliers who should have received treatment (i.e., individuals with $T_i = 1$ and $D_i = 0$) from noncompliers assigned to control; i.e., individuals with $T_i = 0$ and $D_i = 0$. Conditioning on T_i and C_i is important for deriving the estimator for $\tau_{\text{PATT-C}}$ (Eq. 2).

We have made more clear our motivation for conditioning on T_i and C_i when introducing notation in Section 2.1 in the revised manuscript.

2.1.2 Y subscripts

R2 is correct that it would be more appropriate to define Y based on d rather than t. As described in the comment 2.3 below, the original manuscript confused treatment eligibility

T_i with treatment received D_i. Our estimation procedure relies on fitting a response curve to D_i in the RCT, since we cannot actually observe T_i in the population. We have revised the manuscript accordingly.

2.1.3 W_i

With regards to our use of the same W_i across all assumptions, here we are implicitly assuming that the covariates that determine sample selection also determine population treatment assignment and complier status. This is useful not only for notational ease but also reflects our modeling assumption that W_i is the same. In the revised manuscript, we discuss this choice in Sections 2.1 and 3.1.

Moreover, in Section 3.2 of the revised manuscript we describe the need for using candidate learners with built-in variable selection methods, such as the lasso, in the compliance and response model ensembles. The idea is that we input the same W_i and each candidate learner selects the most important covariates for predicting complier status or potential outcomes.

2.1.4 Assumption 2

R2 is correct that while Assumption 2 conditions on W, we use propensity to comply in the estimation. In S.1 of the estimation procedure it becomes clear why we write the assumption this way. Assumption 2 implies that $P(C_i = 1|S_i = 1, T_i = 1, W_i) = P(C_i = 1|S_i = 1, T_i = 0, W_i)$. We estimate the first term to get to the second term. In addition, it would be confusing to have a propensity score here because there are different propensities: propensity to comply given W_i, propensity to be included in the RCT, propensity to receive treatment in the observational sample.

We've included in the revised manuscript when stating Assumption 2 a justification for conditioning on W and it's usefulness in the estimation strategy.

R2 is right in pointing out that the original manuscript doesn't make clear where the assumption is used in the proof. The revised manuscript makes clear – as suggested by R2 – that the last line of the proof follows because S.1 allows us to use "complier controls."

2.1.5 Placebo test

R2 helpfully suggests that we conduct placebo tests to provide evidence supporting the identifying assumptions. R2 is correct that a placebo test for Assumption 2 is not possible because we never observe whether RCT controls would actually take-up treatment if assigned.

However, we are able to compare the observed responses of RCT compliers and the responses of population "compliers," adjusted by the covariate distribution of RCT compliers. Significant difference between the mean outcomes of these groups would indicate that either Assumption 1 (for $d = 1$), or Assumptions 3 and 4 are violated. Section 5.3.1 of the revised manuscript further describes the placebo tests.

2.1.6 Violation of no defiers assumption

R2 justifiably asks for more discussion regarding how the violation of Assumption 6 would impact our empirical findings. Section 5.3.2 discusses two sources of bias arising from the presence of defiers: the proportion of defiers in the study and the difference in the average causal effects of treatment received for compliers and defiers.

In the OHIE, the proportion of defiers is relatively small. We argue that the difference in average causal effects of treatment received for compliers and defiers would have to be considerably large in order for the bias to meaningfully alter the interpretation of the empirical results.

2.2 Prediction threshold and modeling assumptions

We use a standard prediction threshold of 50% to classify compliers, so that complier status C_i is a binary variable. This is necessary for S.3 in the estimation procedure, where we subset to observed compliers assigned to treatment and predicted compliers assigned to control.

We describe the prediction threshold and discuss additional modeling assumptions in Section 3.1 of the revised manuscript.

2.3 Interpretation of PATT

R2 is correct in stating that the comparison between PATT and the Hartman et al. (2015) estimator is not an appropriate comparison. The (unadjusted) PATT estimator in our study is the population-average causal effect of taking up treatment, adjusted according to the covariate distribution of RCT participants. In contrast, the Hartman et al. (2015) estimator is the ITT estimator reweighted according the to covariate distribution of the population. We clarify the distinction in Section 4 of the revised manuscript. We have also corrected the manuscript and to make clear that the response curve is fitted to treatment received D_i rather than treatment eligibility T_i, since we cannot actually observe T_i in the population.

Assumption 1 would indeed be violated if the Hartman et al. (2015) estimator were applied in a setting with noncompliance.

2.4 Relationship to AIR approach

R2 points out that when estimating the average treatment effect on treated compliers in a randomized trial, we usually divide the ITT effect by the compliance rate under the assumptions outlined in Angrist, Imbens, and Rubin (1996), and in this approach we don't need to identify individuals in the control group who are compliers.

We include a discussion of the need to identify compliers — rather than weight the unadjusted PATT estimate by the population compliance rate — in Section 1 of the revised manuscript. We decided to take this approach because the compliance rate is likely to differ between the sample and population, as well as across subgroups. Moreover, our approach allows us to to decompose PATT estimates by covariate group.

3 Reviewer: 3 (R3)

3.1 Generalizability and originality

R3 expressed concern that the compliance and generalizability aspects of the paper are not sufficiently connected to warrant an original contribution. We make two original contributions to the literature on extrapolating RCT results to populations: first, we define the assumptions necessary to identify complier-average causal effects for the target population. The need for this contribution is acknowledged in the discussion of Hartman et al. (2015).

Second, we propose a procedure to estimate this quantity with few additional modeling assumptions. Our estimation procedure is novel in that we are estimating the response surface for RCT compliers and using the predicted values of the response surface model to estimate the potential outcomes of population members who received treatment. We describe in Section 1 of the revision how this approach differs from reweighting methods that use propensity scores to adjust the RCT data (e.g., Stuart et al. 2011). Our estimation strategy is also novel in that we are actually predicting which of the RCT controls would have complied to treatment had they been treated. We argue in the revised Section 1 that this estimation step is important because the compliance rate is likely to differ between the sample and population, as well as across pretreatment covariate group.

3.2 Abstract

R3 points out that it the ultimate inferential goal of the paper – i.e., being able to extrapolate RCT sample estimates to a broader population of interest — is unclear in the abstract. We have rewritten the abstract to make it more clear that we are interested in population-level treatment effect estimates.

3.3 DAG

In Section 2.1 of the revised manuscript, we underscore the importance of W_i in the DAG, as suggested by R3.

R3 asks whether there could there be a role for variables that are causes of S_i but have no direct effect on T_i. This question is similar to R2's question about whether W_i is the same across all identifying assumptions (2.1.3). We have decided to keep W_i the same both for

ease of exposition and because we use the same covariate sets in our estimation procedure — a modeling assumption described in Section 3 of the revised manuscript.

3.4 Clarification re: proof

The "by (k)" comments in the Proof of Theorem 1 are supposed to be numbered assumptions. We have corrected the comments in the Proof accordingly.

Following the suggestion of R3, we have added to the discussion of the Proof the intuitive explanation that conditioning on W_i makes sample selection ignorable under Assumption 3.

3.5 Plausibility of strong ignorability assumptions

We've revised Section 2.1 to include more discussion of potential violations of the strong ignorability assumptions, and Section 5.3 discusses whether these assumptions are plausible for our empirical application. Footnote 3 makes clear why we don't have companion assumptions for non-compliers.

3.6 Clarification re: estimation procedure

3.6.1 Prediction threshold

Similar to R2's comment (2.2), R3 asks for clarification on which prediction threshold we use to classify compliers. The description of the estimation procedure in Section 3 of the revised manuscript clarifies this point.

3.6.2 Relationship to reweighting methods

The original manuscript states that the simulation results shows that a reweighting approach is needed to extrapolate RCT results to a population. This is confusing, because our estimation strategy does not use a reweighting approach, such as assigning individuals in the RCT and population a weight according the inverse propensity score (Stuart et al. 2011). It instead estimates the response surface for RCT compliers and extrapolates the response surface to treated individuals in the population. Each method accomplishes the same goal of adjusting the RCT data to a population, either by using inverse propensity score weights or the predicted values from a response surface model.

We differentiate reweighting methods and response surface approach in Section 1 and also generalize the statement at the end of Section 4.2 of the revised manuscript to include both reweighting and response surface methods.

3.6.3 Description of predictive algorithms

Following R3's suggests, we introduce Section 3.2 in the revised manuscript that introduces the predictive algorithms and the ensemble method. Additionally, we describe the method of evaluating the predictive accuracy of the ensemble.

3.7 Grammatical

We thank R3 for noticing grammatical errors and we have corrected them in the revised manuscript.

References

Hartman, Erin, Richard Grieve, Roland Ramsahai, and Jasjeet S Sekhon. 2015. "From SATE to PATT: Combining experimental with observational studies to estimate population treatment effects." *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 10:1111.

Kowalski, Amanda E. 2016. *Doing More When You're Running LATE: Applying Marginal Treatment Effect Methods to Examine Treatment Effect Heterogeneity in Experiments.* Working Paper, Working Paper Series 22363. National Bureau of Economic Research, June. doi:10.3386/w22363. http://www.nber.org/papers/w22363.

Stuart, Elizabeth A, Stephen R Cole, Catherine P Bradshaw, and Philip J Leaf. 2011. "The use of propensity scores to assess the generalizability of results from randomized trials." *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 174 (2): 369–386.

Taubman, Sarah, Heidi Allen, Bill Wright, Katherine Baicker, and Amy Finkelstein. 2014. "Medicaid Increases Emergency Department Use: Evidence from Oregon's Health Insurance Experiment." *Science* 343, no. 6168 (January): 263–268.

Estimating population average treatment effects from experiments with noncompliance*

Kellie Ottoboni† Jason Poulos‡

December 13, 2018

Abstract

This paper improves on the transportability of clinical trial results to a population by extending a method of estimating population average treatment effects in settings with noncompliance. Simulations show the proposed compliance-adjusted estimator performs better than its unadjusted counterpart when compliance is relatively low and can be predicted by observed covariates. We apply the proposed estimator to measure the effect of Medicaid coverage on health care use for a target population of adults who may benefit from expansions to the Medicaid program, using data from a large-scale health insurance experiment in which a small subset of those randomly selected to receive Medicaid benefits actually enrolled.

*The authors thank Jon McAuliffe and Jas Sekhon and his research group at UC Berkeley for valuable comments. Poulos acknowledges support from the National Science Foundation Graduate Research Fellowship [grant number DGE 1106400]. This work used the Extreme Science and Engineering Discovery Environment (XSEDE) supercomputer Stampede2 at the Texas Advanced Computing Center (TACC) through allocation SES180010.

†Department of Statistics, University of California, Berkeley. email: kellieotto@berkeley.edu.

‡*Corresponding author:* Department of Political Science, University of California, Berkeley. email: poulos@berkeley.edu.

1 Introduction

Randomized control trials (RCTs) are the gold standard for estimating the causal effect of a treatment. An RCT may give an unbiased estimate of the Sample Average Treatment Effect (SATE), but external validity is an issue when the individuals in the RCT are unrepresentative of the actual population of interest. For example, the participants in an RCT in which individuals volunteer to sign up for health insurance may be in poorer health at baseline than the overall population. External validity is particularly relevant to policymakers who want to know how the treatment effect would generalize to the broader population.

This paper extends the literature on extrapolating clinical trial results to populations to deal with noncompliance. Previous approaches to the problem of extrapolating RCT results to a population (Imai, King, and Stuart 2008; Stuart et al. 2011; Hartman et al. 2015) are designed for settings where there is full compliance with treatment. This paper contributes to the literature by defining the assumptions required to identify complier–average causal effects for the target population and proposing an estimation procedure to recover this estimand.

Hartman et al. (2015) propose a method of reweighting the responses of individuals in an RCT according to the distribution of covariates in the target population in order to estimate the population average treatment effect on the treated (PATT). Under a series of assumptions, the PATT is identified from the RCT outcomes. We extend the method to estimate the complier–average causal effects for the target population from RCT data with noncompliance. Noncompliance occurs when individuals who are assigned to the treatment group do not comply with the treatment; for individuals assigned to control, we are unable to observe who would have complied had they been assigned treatment. A prevalent issue in RCTs, noncompliance dilutes the estimated effect of treatment assignment, and biases the intention–to–treat (ITT) estimate towards zero.

The proposed estimator involves estimating the expectation of the response of compliers in the RCT sample, conditional on their covariates, where the expectation is taken over the distribution of population covariates. Note that our estimation strategy differs from

reweighting methods that use propensity scores to adjust the RCT data (Stuart et al. 2011). In this context, the propensity score model predicts participation in the RCT, given pretreatment covariates common to both the RCT and population data. Individuals in the RCT and population are then weighted according to the inverse of the estimated propensity score. We propose an alternative approach of predicting the response surface for RCT compliers and use the predicted values from the response surface model to estimate the potential outcomes of population members who received treatment, given their covariates.

When estimating the average causal effect from an RCT, researchers typically scale the ITT estimate by the compliance rate under the identifying assumptions outlined in Angrist, Imbens, and Rubin (1996). When extrapolating RCT results to a population, one might simply weight the PATT estimate by the population compliance rate in order to yield a population average effect of treatment on treated compliers.[1] However, the compliance rate is likely to differ between the sample and population, as well as across subgroups based on pretreatment covariates. We propose an alternative approach of actually identifying the likely compliers in the control group. By explicitly modeling compliance, this approach allows researchers to decompose population estimates by covariate group and also predict which population members are likely to comply with treatment. Both of these features are useful for policymakers in evaluating the efficacy of policy interventions for subgroups of interest in a population.

We apply the proposed estimator to measure the effect of Medicaid coverage on health care use for a target population of adults who may benefit from government-backed expansions to the Medicaid program. We draw RCT data from a large-scale health insurance experiment, in which only 30% of those randomly selected to receive Medicaid benefits actually enrolled. We find substantial differences between sample and population estimates in terms of race, education, and health status subgroups.

The paper proceeds as follows: Section 2 presents the proposed estimator and the neces-

1. A similar approach is used by Imai, Tingley, and Yamamoto 2013 for estimating average complier indirect effects.

sary assumptions for its identifiability; Section 3 describes the estimation procedure; Section 4 reports the estimator's performance in simulations; Section 5 uses the estimator to identify the effect of extending Medicaid coverage to the low–income adult population in the U.S; Section 6 discusses the results and offers direction for future research.

2 Estimator

We are interested in using the outcomes from an RCT to estimate the average treatment effect on the treated for a target population. Treatment in the population is not assigned at random, but rather may depend on unobserved variables, confounding the effect of treatment on the outcome of interest. RCTs are needed to isolate the effect of treatment. However, strict exclusion criteria for RCTs often result in a sample of individuals whose distribution of covariates differs substantially from the target population.

Ideally, we would take the results of an RCT and reweight the sample such that the reweighted covariates match the those in the population. In practice, one rarely knows the true covariate distribution in the target population. Instead, we consider data from a nonrandomized, observational study in which participants are representative of the target population. The proposed estimator combines RCT and observational data to overcome these issues.

2.1 Assumptions

Let Y_{isd} be the potential outcome for individual i in group s and treatment receipt d. Let S_i denote the sample assignment, where $s = 0$ is the population and $s = 1$ is the RCT. T_i indicates treatment assignment and D_i indicates whether treatment was actually received. Treatment is assigned at random in the RCT, so we observe both D_i and T_i when $S_i = 1$. For compliers in the RCT, $D_i = T_i$.

Let W_i be individual i's observable pretreatment covariates that are related to the sample

selection mechanism for membership in the RCT, treatment assignment in the population, and complier status. Let C_i be an indicator for individual i's compliance to treatment, which is only observable for individuals in the RCT treatment group.

In the population, we suppose that treatment is made available to individuals based on their covariates W_i. Individuals with $T_i = 0$ do not receive treatment, while those with $T_i = 1$ may decide whether or not to accept treatment. For individuals in the population, we only observe D_i — not T_i. We frame Assumptions 3 and 4 in terms of C_i and T_i in order to distinguish among the population controls who should have received treatment (i.e., individuals with $T_i = 1$ and $D_i = 0$) from noncompliers assigned to control (i.e., individuals with $T_i = 0$ and $D_i = 0$).

Assumption 1. *Consistency under parallel studies:*

$$Y_{i0d} = Y_{i1d}, \qquad \forall\, i\,,\ d = \{0, 1\}.$$

Assumption 1 requires that each individual i has the same response to treatment, whether i is in the RCT or not. Compliance status C_i is not a factor in this assumption because we assume that compliance is conditionally independent of sample and treatment assignment for all individuals with covariates W_i.

Assumption 2. *Conditional independence of compliance and assignment:*

$$C_i \perp\!\!\!\perp S_i,\, T_i \mid W_i, \qquad 0 < \mathbb{P}(C_i = 1 \mid W_i) < 1.$$

Assumption 2 implies that $P(C_i = 1|S_i = 1, T_i = 1, W_i) = P(C_i = 1|S_i = 1, T_i = 0, W_i)$, which is useful when predicting the probability of compliance as a function of covariates W_i in the first step of the estimation procedure. Together, Assumptions 1 and 2 ensure that potential outcomes do not differ based on sample assignment or receipt of treatment.

Assumption 3. *Strong ignorability of sample assignment for treated:*

$$(Y_{i01}, Y_{i11}) \perp\!\!\!\perp S_i \mid (W_i, T_i = 1, C_i = 1), \qquad 0 < \mathbb{P}(S_i = 1 \mid W_i, T_i = 1, C_i = 1) < 1.$$

Assumption 3 ensures the potential outcomes for treatment are independent of sample assignment for individuals with the same covariates W_i and assignment to treatment.[2] We make a similar assumption for the potential outcomes under control:

Assumption 4. *Strong ignorability of sample assignment for controls:*

$$(Y_{i00}, Y_{i10}) \perp\!\!\!\perp S_i \mid (W_i, T_i = 1, C_i = 1), \qquad 0 < \mathbb{P}(S_i = 1 \mid W_i, T_i = 1, C_i = 1) < 1.$$

RCT study designs that apply restrictive exclusion criteria may increase the likelihood that there are unobserved differences between the RCT and target population, which would violate the strong ignorability assumptions.[3]

Interference undermines the framework because it creates more than two potential outcomes per participant, depending on the treatment receipt of other participants (Rubin 1990). We therefore assume no interference between units:

Assumption 5. *The potential outcomes Y_{isd} do not depend on D_j, $\forall j \neq i$.*

Figure 1 shows Assumptions 2, 3, and 4 in a directed acyclic graph. Treatment assignment T_i may only depend on C_i through W_i, and the potential outcomes (Y_{is0}, Y_{is1}) may only depend on S_i through W_i. From the internal validity standpoint, the role of W_i is critical: if any relevant observed covariates are not controlled, then there is a backdoor pathway from T_i back to W_i and into Y_{isd}. We use the same W_i across all identifying assumptions, which implicitly assumes that the observable covariates that determine sample selection

2. Throughout, we assume individuals are sampled randomly from an infinite population.

3. Note that Assumptions 3 and 3 also imply strong ignorability of sample assignment for treated and control noncompliers since we assume in that compliance is also independent of sample and treatment assignment, conditional on W_i (Assumption 2). However, we are interested only on modeling the response surfaces for compliers.

also determine population treatment assignment and complier status. This choice reflects a modeling assumption of the estimation procedure described in Section 3.

Figure 1: here

We additionally include Assumptions 6 and 7, which are made by Angrist, Imbens, and Rubin (1996) to ensure identifiability. The former assumption ensures that crossover is only possible from treatment to control:

Assumption 6. *No defiers:*

$$T_i \geq D_i, \qquad \forall\, i\,,\ d, t = \{0, 1\}.$$

Assumption 7 ensures treatment assignment affects the response only through the treatment received. In particular, the treatment effect may only be nonzero for compliers.

Assumption 7. *Exclusion restriction: For noncompliers,*

$$Y_{i11} = Y_{i10}, \qquad \forall\, i.$$

2.2 PATT-C

The estimand of interest is the Population Average Treatment Effect on Treated Compliers (PATT-C):

$$\tau_{\text{PATT-C}} = \mathbb{E}\left(Y_{i01} - Y_{i00} \mid S_i = 0, D_i = 1\right). \tag{1}$$

PATT-C is interpreted as the average treatment effect on those in the population who receive treatment. It includes individuals who actually receive the treatment, but does not

include those who are eligible for treatment and do not accept it (i.e., noncompliers). The following theorem relates the treatment effect in the RCT to the treatment effect in the population.

Theorem 1. *Under Assumptions 1 – 7,*

$$\tau_{PATT\text{-}C} = \mathbb{E}_{11}\left[\mathbb{E}\left(Y_{i01} \mid S_i = 0, D_i = 1, W_i\right)\right] - \mathbb{E}_{11}\left[\mathbb{E}\left(Y_{i00} \mid S_i = 0, D_i = 1, W_i\right)\right] \quad (2)$$

where $\mathbb{E}_{11}\left[\mathbb{E}(\cdot \mid \ldots, W_i)\right]$ denotes the expectation with respect to the distribution of W_i for RCT compliers.

Proof. We separate the expectation linearly into two terms and consider each individually.

$$\begin{aligned}
\mathbb{E}\left(Y_{i01} \mid S_i = 0, D_i = 1\right) &= \mathbb{E}\left(Y_{i11} \mid S_i = 0, D_i = 1\right) && \text{by Assumption 1} \\
&= \mathbb{E}\left(Y_{i11} \mid S_i = 0, T_i = 1, C_i = 1\right) && \text{by Assumption 6} \\
&= \mathbb{E}_{11}\left[\mathbb{E}\left(Y_{i11} \mid S_i = 0, T_i = 1, C_i = 1, W_i\right)\right] \\
&= \mathbb{E}_{11}\left[\mathbb{E}\left(Y_{i11} \mid S_i = 1, T_i = 1, C_i = 1, W_i\right)\right] && \text{by Assumption 3} \\
&= \mathbb{E}_{11}\left[\mathbb{E}\left(Y_{i11} \mid S_i = 1, D_i = 1, W_i\right)\right]
\end{aligned}$$

Intuitively, conditioning on W_i makes sample selection ignorable under Assumption 3. This is the critical connector between the third and fourth lines of the first expectation derivation.

$$
\begin{aligned}
\mathbb{E}\left(Y_{i00} \mid S_i = 0, D_i = 1\right) &= \mathbb{E}\left(Y_{i10} \mid S_i = 0, D_i = 1\right) && \text{by Assumption 1} \\
&= \mathbb{E}\left(Y_{i10} \mid S_i = 0, T_i = 1, C_i = 1\right) && \text{by Assumption 6} \\
&= \mathbb{E}_{11}\left[\mathbb{E}\left(Y_{i10} \mid S_i = 1, T_i = 1, C_i = 1, W_i\right)\right] && \text{by Assumption 4} \\
&= \mathbb{E}_{11}\left[\mathbb{E}\left(Y_{i10} \mid S_i = 1, T_i = 0, C_i = 1, W_i\right)\right] && \text{by Assumption 2}
\end{aligned}
$$

The last line follows because Assumption 2 allows us to use RCT controls who would have complied had they been assigned to treatment. Finally, the result follows by plugging these two expressions into Eq. (1). □

3 Estimation procedure

There are two challenges in turning Theorem 1 into an estimator of $\tau_{\text{PATT-C}}$ in practice. First, we must estimate the inner expectation over potential outcomes of compliers in the RCT. In the empirical example, we use an ensemble of algorithms (Laan, Polley, and Hubbard 2007) to estimate the response surface for compliers in the RCT, given their covariates. Thus, the first term in the expression for $\tau_{\text{PATT-C}}$ is estimated by the weighted average of points on the response surface, evaluated for each treated population member's potential outcome under treatment. The second term is estimated by the weighted average of points on the response surface, evaluated for each treated population member's potential outcome under control.

The second challenge is that we cannot observe which individuals are included in the estimation of the second term. In the RCT control group, C_i is unobservable, as they always receive no treatment ($D_i = 0$). We must estimate the second term of Eq. (2) by predicting who in the control group would be a complier had they been assigned to treatment. An alternative approach is to simply weight the PATT estimate by the population compliance

rate in order to yield a population average effect of treatment on treated compliers. However, the compliance rate is likely to differ between the sample and population, as well as across subgroups. Explicitly modeling compliance allows us to decompose PATT-C estimates by subgroup according to covariates common to both RCT and observational datasets.

The procedure for estimating $\tau_{\text{PATT-C}}$ using Theorem 1 is as follows:

S.1 Using the group assigned to treatment in the RCT ($S_i = 1, T_i = 1$), train a model (or an ensemble of models) to predict the probability of compliance as a function of covariates W_i.

S.2 Using the model from S.1, predict who in the RCT assigned to control *would have* complied to treatment had they been assigned to the treatment group. We use a standard prediction threshold of 50% in order classify compliers, $C_i = 1$.[4]

S.3 For the observed compliers assigned to treatment and predicted compliers assigned to control, train a model to predict the response using W_i and D_i, which gives $\mathbb{E}(Y_{i1d} \mid S_i = 1, D_i = d, W_i)$ for $d \in \{0, 1\}$.

S.4 For all individuals who received treatment in the population ($S_i = 0, D_i = 1$), estimate their potential outcomes using the model from S.3, which gives Y_{i0d} for $d \in \{0, 1\}$. The mean counterfactual Y_{i01} minus the mean counterfactual Y_{i00} is the estimate of $\tau_{\text{PATT-C}}$.

Assumptions 3 and 4 are particularly important for estimating $\tau_{\text{PATT-C}}$: the success of the proposed estimator hinges on the assumption that the response surface is the same for compliers in the RCT and target population. If this does not hold, then the potential outcomes Y_{i10} and Y_{i11} for target population individuals cannot be estimated using the model from S.3.[5]

4. Adjusting the prediction threshold upward would result in more accurate classifications, although we do not explore this approach.

5. Section 5.3 discusses whether the strong ignorability assumptions are plausible in the empirical application.

3.1 Modeling assumptions

In addition to the identification assumptions, we require additional modeling assumptions for the estimation procedure. First, we assume that the W_i that determine sample selection also determine population treatment assignment and complier status. As pointed out in Section 2.1, we also require that W_i is complete because if any relevant elements of W_i are not controlled, then there is a backdoor pathway from T_i back to W_i and into Y_{isd}. Lastly, we assume that the compliance model is accurate in predicting compliance in the training sample of RCT participants assigned to treatment and also generalizable to RCT participants assigned to control (S.1 and S.2). Section 3.2 below describes the method of evaluating the generalizability of the compliance model.

3.2 Ensemble method

In the empirical application, we use the weighted ensemble method described in Laan, Polley, and Hubbard (2007) for S.1 and S.3 of the estimation procedure. This ensemble method combines algorithms with a convex combination of weights based on minimizing cross-validated error. It is shown to control for overfitting and outperforms single algorithms selected by cross-validation (Polley and Van Der Laan 2010).

We choose a variety of candidate algorithms to construct the ensemble, with a preference towards algorithms that tend to outperform in supervised classification tasks. We also have a preference for algorithms that have a built-in variable selection property. The idea is that we input the same W_i and each candidate algorithm selects the most important covariates for predicting compliance status or potential outcomes.[6] We select three types of candidate algorithms: nonparametric additive regression models (Buja, Hastie, and Tibshirani 1989); L1 or L2-regularized linear models (e.g., Lasso or ridge regression, respectively) (Tibshirani et al. 2012); and ensembles of decision trees (i.e., random forests) (Breiman 2001). L1-

6. A potential concern when predicting potential outcomes is that the algorithm might shrink the treatment received predictor to zero, which would result in no difference between counterfactual potential outcomes.

regularized linear models are important for the application due to their variable selection properties: lasso is particularly attractive because it tends to shrink all but one of the coefficients of correlated covariates to zero.

4 Simulations

We conduct a simulation study to compare the performance of the PATT and PATT-C estimators. For comparison, we compare the population estimates to the SATE, which is the ITT effect estimated from the RCT sample adjusted by the sample compliance rate.

The simulation is designed so that the effect of treatment is heterogeneous and depends on covariates which are different in the RCT and target population. The design satisfies the conditional independence assumptions in Figure 1.

4.1 Simulation design

In the simulation, RCT eligibility, complier status, and treatment assignment in the population depend on multivariate normal covariates $(W_i^1, W_i^2, W_i^3, W_i^4)$ with mean $(0.5, 1, -1, -1)$ and covariances $\text{Cov}(W_i^1, W_i^2) = \text{Cov}(W_i^1, W_i^4) = \text{Cov}(W_i^2, W_i^4) = \text{Cov}(W_i^3, W_i^4) = 1$ and $\text{Cov}(W_i^1, W_i^3) = \text{Cov}(W_i^2, W_i^3) = 0.5$. The first three covariates are observed by the researcher and W_i^4 is unobserved.

The equation for selection into the RCT is

$$S_i = \mathbb{I}(e_2 + g_1 W_i^1 + g_2 W_i^2 + g_3 W_i^3 + e_4 W_i^4 + R > 0),$$

where R is standard normal. The parameter e_2 varies the fraction of the population eligible for the RCT and e_4 varies the degree of confounding with sample selection. We set the constants g_1, g_2, and g_3 to be 0.5, 0.25, and 0.75, respectively.

Complier status is determined by

$$C_i = \mathbb{I}(e_3 + h_2 W_i^2 + h_3 W_i^3 + e_5 W_i^4 + Q > 0),$$

where Q is standard normal, e_3 varies the fraction of compliers in the population, and e_5 varies the degree of confounding with treatment assignment. We set the constants h_2 and h_3 to 0.5.

For individuals in the population ($S_i = 0$), treatment is assigned by

$$T_i = \mathbb{I}(e_1 + f_1 W_i^1 + f_2 W_i^2 + e_6 W_i^4 + V > 0),$$

where V is standard normal. Varying e_1 changes the fraction eligible for treatment in the population and e_6 varies the degree of confounding with sample selection. We set the constants f_1 and f_2 to 0.25 and 0.75, respectively. For individuals in the RCT ($S_1 = 1$), treatment assignment is a sample from a Bernoulli distribution with probability $p = 0.5$. We set treatment received D_i according to T_i and C_i: $D_i = T_i$ if $C_i = 1$ and $D_i = 0$ if $C_i = 0$.

Finally, the response is determined by

$$Y_{isd} = a + bD + c_1 W_i^1 + c_2 W_i^2 + dU.$$

We assume that the treatment effect b is heterogeneous depending on W_i^1: $b = 1$ if $W_i^1 > 0.75$ and $b = -1$ if $W_i^1 \leq 0.75$. We set a, c_1, and d to 1 and c_2 to 2. U is standard normal and $U, V, R, Q, (W_i^1, W_i^2, W_i^3, W_i^4)$ are mutually independent.

We generate a population of 30,000 individuals and randomly sample 5,000. Those among the 5,000 who are eligible for the RCT ($S_i = 1$) are selected. Similarly, we sample 5,000 individuals from the population and select those who are not eligible for the RCT ($S_i = 0$):

these are the observational study participants.[7]

We set each individual's treatment received D_i according to their treatment assignment and complier status and observe their responses Y_{isd}. In this design, the manner in which S_i, T_i, D_i, C_i, and Y_{isd} are simulated ensures that Assumptions 1 – 7 hold.

In the assigned-treatment RCT group ($S_i = 1, T_i = 1$), we train a gradient boosting algorithm (Friedman 2001) on the covariates to predict who in the control group ($S_i = 1, T_i = 0$) would comply with treatment ($C_i = 1$), which is unobservable. These individuals *would have* complied had they been assigned to the treatment group. For this group of observed compliers to treatment and predicted compliers from the control group of the RCT, we estimate the response surface using gradient boosting with features (W_i^1, W_i^2, W_i^3) and D_i. The PATT-C is estimated according to the estimation procedure outlined above.

4.2 Simulation results

We vary each of the parameters e_1, e_2, e_3, e_4, e_5, and e_6 along a grid of five random standard normal values in order to generate different combinations of rates of compliance, treatment eligibility, RCT eligibility in the population, and confounding. For each possible combination of the six parameters, we run the simulation ten times and compute the average root mean squared error (RMSE) of PATT-C, PATT, and the SATE. All other parameters are held constant. The PATT and PATT-C estimates are obtained by estimating the response surface on all individuals in the RCT and applying S.4 of the estimation procedure to the population members.[8]

Figure 2 shows the relationship between the percent of compliers in the whole population, the percentage of people in the population eligible to participate in the RCT, and the RMSE of the PATT and PATT-C estimators. The PATT estimator performs badly when the

7. This set-up mimics the reality that a population census is usually impossible.

8. Note that the PATT estimator here is the population-average causal effect of taking up treatment, adjusted according to the covariate distribution of RCT participants. In contrast, the Hartman et al. (2015) population estimator is the ITT estimator reweighted according the to covariate distribution of the population.

compliance rate is low, whereas the PATT-C estimator is comparatively insensitive to changes in the compliance rate. A similar pattern emerges when the compliance rate varies with the population treatment rate (Figure A1).

Figure 2: here

Figure 3 compares the RMSE of PATT and PATT-C with the SATE at varying levels of compliance in the total population. PATT-C is relatively invariant to changes in the compliance rate and outperforms both PATT and SATE in terms of minimizing RMSE when the compliance rate is below 70%. For high levels of compliance, the SATE tends to estimate the average causal effects for the target population as closely than as PATT or PATT-C.

Figures A2, A3, and A4 explore how the degrees of confounding in the mechanisms that determine sample selection, treatment assignment, and compliance affect estimation error. PATT-C tends to be invariant to increases in the degree of confounding, whereas PATT is sensitive to confounding in the sample selection mechanism. The SATE estimates are generally more variable than the population estimates due to the sample estimator's inability to account for differences in pretreatment covariates between the RCT sample and target population.

Figure 3: here

5 Application: Medicaid and health care use

We apply the proposed estimator to measure the effect of Medicaid coverage on health care use for a target population of adults who may benefit from expansions to the Medicaid program. In particular, we examine the population of nonelderly adults in the U.S. with household incomes at or below 138% of the Federal Poverty Level (FPL) — which amounts to $32,913 for a four–person household in 2014 — who may be eligible for Medicaid following the Affordable Care Act (ACA) expansion.

5.1 RCT sample

We draw RCT data from the Oregon Health Insurance Experiment (OHIE) (Finkelstein et al. 2012; Katherine Baicker et al. 2013; Baicker et al. 2014; Taubman et al. 2014). In 2008, approximately 90,000 uninsured low-income adults participated in the OHIE to receive Medicaid benefits.[9] Treatment occurred at the household level: participants selected by the lottery won the opportunity for themselves and any household member to apply for Medicaid. Within a sample of 74,922 individuals representing 66,385 households, 29,834 participants were selected by the lottery; the remaining 45,008 participants served as controls in the experiment. Participants in selected households received benefits if they returned an enrollment application within 45 days of receipt. Among participants in selected households, about 60% mailed back applications and only 30% successfully enrolled.[10]

The response data originate from a mail survey that was administered to participants over July and August 2009 ($n = 23,741$ survey respondents). We use the same definition of insurance coverage as Finkelstein et al. (2012) to form the measure of compliance, which is a binary variable indicating whether the participant was enrolled in any Medicaid program

9. Eligible participants include Oregon residents (US citizens or legal immigrants) aged 19 to 64 not otherwise eligible for public insurance, who have been without insurance for six months, and have income below the FPL and assets below $2,000.

10. About half of the returned applications were deemed ineligible, primarily due to failure to demonstrate income below the FPL. Enrolled participants were required to recertify their eligibility status every six months.

during the study period. The OHIE data include pretreatment covariates for gender, age, race, ethnicity, health status, education, and household income.

The outcomes of interest are binary variables for any emergency room (ER) and outpatient visits in the past 12 months. ER use is an important outcome because it is the main delivery system through which the the uninsured receive health care. The uninsured could potentially receive higher quality and less affordable healthcare through outpatient visits. An important question for policymakers is whether Medicaid expansions will decrease ER utilization by the previously uninsured.

Subsequent research calls in to question the external validity of the OHIE, which resulted in the counterintuitive finding that Medicaid increased ER use among RCT participants (Finkelstein et al. 2012; Taubman et al. 2014). For example, quasi-experimental studies on the impact of the 2006 Massachusetts health reform — which served as a model for the ACA — show that ER use decreased or remained constant following the reform (Miller 2012; Kolstad and Kowalski 2012). A challenge to the external validity of the OHIE is that it's exclusion criteria was likely more restrictive than government health insurance expansions.

5.2 Observational data

We acquire data on the target population from the National Health Interview Study (NHIS) for years 2008 to 2017 (National Center for Health Statistics).[11] We restrict the sample to respondents with income below 138% of the FPL and who are uninsured or on Medicaid and select covariates on respondent characteristics that match the OHIE pretreatment covariates. The outcomes of interest from NHIS are variables on ER and outpatient visits in the past 12 months. We use a recoded variable that indicates whether respondents are on Medicaid as an analogue to the OHIE compliance measure.

11. A possible limitation of this application is that it ignores the complex sampling techniques of the NHIS sample design such as differential sampling, which is discussed in detail in Parsons et al. (2014).

5.3 Verifying assumptions

In order for $\tau_{\text{PATT-C}}$ to be identified, Assumptions 1 – 7 must be met. Assumption 1 ensures that potential outcomes for participants in the target population would be identical to their outcomes in the RCT if they had been randomly assigned their observed treatment. In the empirical application, medicaid coverage for uninsured individuals was applied in the same manner in the RCT as it is in the population. Differences in potential outcomes due to sample selection might arise, however, if there are differences in the mail surveys used to elicit health care use responses between the RCT and the nonrandomized study.

We cannot directly test Assumptions 3 and 4, which state that potential outcomes for treatment and control are independent of sample assignment for individuals with the same covariates and assignment to treatment. The assumptions are only met if every possible confounder associated with the response and the sample assignment is accounted for. In estimating the response surface, we use all demographic, socioeconomic, and pre-existing health condition data that were common in the OHIE and NHIS data. Potentially important unobserved confounders include the number of hospital and outpatient visits in the previous year, proximity to health services, and enrollment in other federal programs.

The final two columns of Table A1 compares RCT participants selected for Medicaid with population members on Medicaid. Compared to the RCT compliers, the target population "compliers" are predominantly female, younger, more racially and ethnically diverse, less educated, and live in higher income households. Diagnoses of diabetes, asthma, high blood pressure, and heart disease are more common among the population on Medicaid then the RCT treated.

Strong ignorability assumptions may also be violated due to the fact that the OHIE applied a more stringent exclusion criteria compared to the NHIS sample. While the RCT and population sample both screened for individuals below the FPL, only the RCT required those enrolled to recertify their eligibility status every six months.

A violation of no-interference (Assumption 5) biases the estimate of $\tau_{\text{PATT-C}}$ if, for in-

stance, treated participants' Medicaid coverage makes control participants more likely to visit the ER. Interference is less likely in this experimental set–up because treatment occurs at the household level.

Assumption 2 is violated if assignment to treatment influences the compliance status of individuals with the same covariates. The compliance ensemble can accurately classify compliance status for 77% of treated RCT participants with only the covariates — and not treatment assignment — as model inputs.[12] This gives evidence in favor of the conditional independence assumption.

The exclusion restriction (Assumption 7) ensures treatment assignment affects the response only through enrollment in Medicaid. It is reasonable that a person's enrollment in Medicaid, not just their eligibility to enroll, would affect their hospital use. For private health insurance one might argue that eligibility may be be negatively correlated with hospital use, as people with pre-existing conditions are less often eligible yet go to the hospital more frequently. This should not be the case with a federally funded program such as Medicaid.

5.3.1 Placebo tests

Similar to the procedure proposed by (Hartman et al. 2015), we conduct placebo tests to check whether the average outcomes differ between the RCT compliers on Medicaid and the adjusted population "compliers" on Medicaid.[13] If the placebo tests detect a significant difference between the mean outcomes of these groups, it would indicate that either Assumption 1 (for $d = 1$), or Assumptions 3 and 4 are violated.

Table A3 reports the results of placebo tests, comparing the mean outcomes of RCT compliers against the mean outcomes of adjusted population "compliers." The former quantity is calculated from the observed RCT sample and the latter quantity is the mean counterfactual Y_{i11} estimated from S.4 of the estimation procedure. Tests of equivalence between the

12. The compliance ensemble is evaluated in terms of 10–fold cross–validated MSE. The distribution of MSE for the ensemble and its candidate algorithms are provided in Table A5.

13. Note that a placebo test for Assumption 2 is not possible because we never observe whether RCT controls would actually take-up treatment if assigned.

two groups indicate that the differences across each outcome are not statistically significant. These results imply that the PATT-C estimator is not biased by differences in how Medicaid is delivered or health outcomes are measured between the RCT and population, or by differences in sample or population members' unobserved characteristics.

5.3.2 Sensitivity to no defiers assumption

Angrist, Imbens, and Rubin (1996) show that the bias due to violations of Assumption 6 is equivalent to the difference of average causal effects of treatment received for compliers and defiers, multiplied by the relative proportion of defiers, $\mathbb{P}(i \text{ is a defier})/(\mathbb{P}(i \text{ is a complier}]) - \mathbb{P}(i \text{ is a defier}))$.

Table A2 reports the distribution of participants in the OHIE by status of treatment assignment and treatment received. Assumption 6 does not hold due to the presence of defiers; i.e., participants who were assigned to control and enrolled in Medicaid during the study period. About 6.7% of the RCT sample were assigned to control but were enrolled in Medicaid ($T_i < D_i$) and 65.5% of the sample complied with treatment assignment ($D_i = T_i$), which results in a bias multiplier of 0.11. Suppose that the difference of average causal effects of Medicaid received on ER use for compliers and defiers is 1.2%. The resulting bias is only 0.1%, which would not meaningfully alter the interpretation of the SATE or PATT-C estimates reported below.

5.4 Empirical results

We compare PATT-C and PATT estimates for ER and outpatient use. We obtain estimates for the overall group of participants and subgroups according to sex, age, race, health status, education, and household income. Subgroup treatment effects are estimated by taking differences across response surfaces for a given covariate subgroup, and response surfaces are estimated with the ensemble mean predictions. We use treatment received, number of household members, and the subgroup covariates as features in the response models. We generate 95% confidence intervals for these estimates using 1,000 bootstrap samples.

Table A4 presents the PATT-C estimates, which indicate that Medicaid coverage has a positive, but considerably smaller effect on the number of ER and outpatient visits. For comparison, Finkelstein et al. (2012) reports population estimates of the effect of Medicaid coverage on *the number of* ER and out-patient visits using 2004–2009 NHIS data on adults aged 19–64 below 100 percent of the federal poverty line ($n = 15,528$). Finkelstein et al. (2012) estimates Medicaid coverage significantly increases the number of ER visits by 0.08 [0.05, 0.12] and increases the number of outpatient visits by 1.45 [1.33, 1.57].

Figures A5, A6, and A7 examine heterogeneous treatment effect estimates on ER and outpatient use in the population. While this study is the first to our knowledge to estimate heterogeniety in treatment effects for the target population, Taubman et al. (2014) and Kowalski (2016) perform subgroup analyses on the RCT sample. Similar to the PATT-C estimates, Taubman et al.'s [2014] subgroup analyses indicate that increases in ER use due to Medicaid are significantly larger for younger individuals and those with high school-level education.[14]

6 Discussion

The simulations presented in Section 4 show that the PATT-C estimator outperforms its unadjusted counterpart when the compliance rate is low. PATT gives the ITT effect extrapolated those who take treatment in the population, which tends to underestimate the average treatment effect on compliers. Of course, the simulation results depend on the particular way we parameterized the compliance, selection, treatment assignment, and response schedules.

In particular, the strength of correlation between the covariates and compliance governs how well the estimator will perform, since S.1 of the estimation procedure is to predict who *would be* a complier in the RCT control group, had they been assigned to treatment. If it is

14. Kowalski (2016) perform subgroup analyses on OHIE sample data and find larger increases in ER use as a result of Medicaid for men, English speakers, and individuals enrolled in a food stamp program prior to the lottery.

difficult to predict compliance using the observed covariates, then the estimator will perform badly because of noise introduced by incorrectly treating noncompliers as compliers. Further research should be done into ways to test how well the model of compliance works in the population or explore models to more accurately predict compliance in RCTs. Accurately predicting compliance is not only essential for yielding unbiased estimates of the average causal effects for target populations, it is also useful for researchers and policymakers to know which groups of individuals are unlikely to comply with treatment.

In the OHIE trial, only about 30% of those selected to receive Medicaid benefits actually enrolled. The compliance ensemble accurately classified compliance status for 77% of treated RCT participants using only the pretreatment covariates as features. While we don't know how well the compliance ensemble predicts for the control group, the control group should be similar to the treatment group on pretreatment covariates because of the RCT randomization. The model's performance on the training set suggests that compliance is not purely random and depends on observed covariates. This gives evidence in favor of using the proposed estimator.

In the empirical application, the sample population differs in several dimensions from the target population of individuals who will be covered by other Medicaid expansions, such as the ACA expansion to cover all adults up to 138% of the FPL. For instance, the RCT participants are disproportionately white urban–dwellers (Taubman et al. 2014). The RCT participants volunteered for the study and therefore may be in poorer health compared to the target population. These differences in baseline covariates make reweighting or response surface methods necessary to extend the RCT results to the population.

Explicitly modeling compliance allows us to decompose population estimates by subgroup according to pretreatment covariates common to both RCT and observational datasets; e.g, demographic variables, pre–existing conditions, and insurance coverage. We find substantial differences between sample and population estimates in terms of race, education, and health status subgroups. This pattern is expected because RCT participants volunteered for the

study and are predominately white and educated.

References

Angrist, Joshua D., Guido W. Imbens, and Donald B. Rubin. 1996. "Identification of Causal Effects Using Instrumental Variables." *Journal of the American Statistical Association* 91, no. 434 (June): 444–455.

Baicker, K, A Finkelstein, J Song, and S Taubman. 2014. "The Impact of Medicaid on Labor Market Activity and Program Participation: Evidence from the Oregon Health Insurance Experiment." *The American Economic Review* 104 (5): 322.

Baicker, Katherine, Sarah L Taubman, Heidi L Allen, Mira Bernstein, Jonathan H Gruber, Joseph P Newhouse, Eric C Schneider, Bill J Wright, Alan M Zaslavsky, and Amy N Finkelstein. 2013. "The Oregon experiment—effects of Medicaid on clinical outcomes." *New England Journal of Medicine* 368 (18): 1713–1722.

Breiman, Leo. 2001. "Random forests." *Machine Learning* 45 (1): 5–32.

Buja, Andreas, Trevor Hastie, and Robert Tibshirani. 1989. "Linear smoothers and additive models." *The Annals of Statistics:* 453–510.

Finkelstein, Amy, Sarah Taubman, Bill Wright, Mira Bernstein, Jonathan Gruber, Joseph P Newhouse, and Heidi Allen. 2012. "The Oregon Health Insurance Experiment: Evidence from the First Year." *The Quarterly Journal of Economics* 127 (3): 1057.

Friedman, Jerome H. 2001. "Greedy function approximation: A gradient boosting machine." *Annals of Statistics:* 1189–1232.

Hartman, Erin, Richard Grieve, Roland Ramsahai, and Jasjeet S Sekhon. 2015. "From SATE to PATT: Combining experimental with observational studies to estimate population treatment effects." *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 10:1111.

Imai, Kosuke, Gary King, and Elizabeth Stuart. 2008. "Misunderstandings Among Experimentalists and Observationalists about Causal Inference." *Journal of the Royal Statistical Society, Series A* 171, part 2:481–502.

Imai, Kosuke, Dustin Tingley, and Teppei Yamamoto. 2013. "Experimental designs for identifying causal mechanisms." *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 176 (1): 5–51.

Kolstad, Jonathan T, and Amanda E Kowalski. 2012. "The impact of health care reform on hospital and preventive care: evidence from Massachusetts." *Journal of Public Economics* 96 (11-12): 909–929.

Kowalski, Amanda E. 2016. *Doing More When You're Running LATE: Applying Marginal Treatment Effect Methods to Examine Treatment Effect Heterogeneity in Experiments.* Working Paper, Working Paper Series 22363. National Bureau of Economic Research, June. doi:10.3386/w22363. http://www.nber.org/papers/w22363.

Laan, Mark J van der, Eric C Polley, and Alan E Hubbard. 2007. "Super learner." *Statistical Applications in Genetics and Molecular Biology* 6 (1).

Miller, Sarah. 2012. "The effect of insurance on emergency room visits: an analysis of the 2006 Massachusetts health reform." *Journal of Public Economics* 96 (11-12): 893–908.

National Center for Health Statistics. *National Health Interview Survey, 2008–2013.* http://www.cdc.gov/nchs/nhis.htm. [Online; accessed 06-April-2015].

Parsons, Van L, Christopher L Moriarity, Kimball Jonas, Thomas F Moore, Karen E Davis, and Linda Tompkins. 2014. "Design and estimation for the National Health Interview Survey, 2006–2015." *National Center for Health Statistics. Vital and Health Statistics* 2 (165): 1–53.

Polley, Eric C, and Mark J Van Der Laan. 2010. *Super learner in prediction.* Working Paper, U.C. Berkeley Division of Biostatistics Working Paper Series 266. Division of Biostatistics, University of California, Berkeley. http://biostats.bepress.com/ucbbiostat/paper266.

Rubin, Donald B. 1990. "Comment: Neyman (1923) and Causal Inference in Experiments and Observational Studies." *Statistical Science* 5 (4): 472–480.

Stuart, Elizabeth A, Stephen R Cole, Catherine P Bradshaw, and Philip J Leaf. 2011. "The use of propensity scores to assess the generalizability of results from randomized trials." *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 174 (2): 369–386.

Taubman, Sarah, Heidi Allen, Bill Wright, Katherine Baicker, and Amy Finkelstein. 2014. "Medicaid Increases Emergency Department Use: Evidence from Oregon's Health Insurance Experiment." *Science* 343, no. 6168 (January): 263–268.

Tibshirani, Robert, Jacob Bien, Jerome Friedman, Trevor Hastie, Noah Simon, Jonathan Taylor, and Ryan J Tibshirani. 2012. "Strong rules for discarding predictors in lasso-type problems." *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* 74 (2): 245–266.

Appendix



Figure A1: Simulated RMSE, binned by compliance rate and treatment rate.



Figure A2: Simulated RMSE of PATT-C, PATT, and SATE, according to degree of confounding in compliance.



Figure A3: Simulated RMSE of PATT-C, PATT, and SATE, according to degree of confounding in treatment assignment.



Figure A4: Simulated RMSE of PATT-C, PATT, and SATE, according to degree of confounding in sample selection.

Table A1: Pretreatment covariates and responses for OHIE and NHIS respondents by Medicaid coverage status.

	OHIE no Medicaid $n = 4,519$		OHIE Medicaid $n = 6,100$		NHIS Medicaid $n = 6,261$	
Covariate	**n**	%	**n**	%	**n**	%
Sex:						
Female	2,538	56.2	3506	57.5	4,288	68.5
Age:						
19-49	1,288	28.5	1,625	26.6	4324	69.1
50-64	3,231	71.5	4,475	73.4	1,937	30.9
Race:						
White	3,956	87.5	5,183	85.0	3,902	62.3
Black	193	4.3	247	4.0	1,723	27.5
Hispanic	264	5.8	538	8.8	1,570	25.1
Health status:						
Diabetes	459	10.2	637	10.4	866	13.8
Asthma	823	18.2	1,094	17.9	1272	20.3
High blood pressure	1,362	30.1	1,705	27.9	2,166	34.6
Heart condition	120	2.7	189	3.1	529	8.4
Education:						
Less than high school	858	19.0	1,154	18.9	1,942	31.0
High school diploma or GED	2,589	57.3	3,279	53.8	2,076	33.2
Voc. training / 2-year degree	804	17.8	1,186	19.4	1,810	28.9
4-year college degree or more	268	5.9	481	7.9	433	6.9
Income:						
< $10k	4,518	100.0	4,111	67.4	2,588	41.3
$10k-$25k	1	0.0	1,616	26.5	3,098	49.5
> $25k	0	0.0	373	6.1	575	9.2
Binary response	**n**	%	**n**	%	**n**	%
Any ER visit	1,377	25.4	1,301	25.1	1,659	26.5
Continuous response	$\bar{\mathbf{x}}$	**sd**	$\bar{\mathbf{x}}$	**sd**	$\bar{\mathbf{x}}$	**sd**
# ER visits	0.44	0.95	0.44	0.99	0.48	1.0
# outpatient visits	1.9	3.01	1.9	2.8	2.08	2.3

Table A2: Distribution of OHIE participants by status of treatment assignment (T_i) and treatment received (D_i).

	$D_i = 0$	$D_i = 1$	n
$T_i = 0$	10,010	1,556	11,566
$T_i = 1$	6,446	5,193	11,639
n	16,456	6,749	23,205

Table A3: Placebo test results comparing the mean outcomes of RCT compliers and adjusted population "compliers."

Outcome	RCT complier mean	Adjusted pop. "complier" mean	Difference	p-value
Any ER visit	0.25	0.25	0.0001	0.97
# ER vists	0.45	0.45	0.002	0.85
# outpatient visits	1.90	1.94	-0.03	0.26

Notes: p-values for difference-in-means calculated from two-sided t-test.

Table A4: Comparison of population and sample estimates.

Estimator \ Outcome	Any ER visit	# ER visits	# outpatient visits
PATT-C	0.0001 [0.0001, 0.0001]	0.0005 [0.0002, 0.0008]	0.002 [0.002, 0.002]
PATT	0.0006 [0.0005, 0.0007]	-0.004 [-0.005, -0.004]	0.02 [0.02, 0.02]
SATE	-0.001 [-0.02, 0.02]	0.005 [-0.05, 0.06]	-0.02 [-0.19, 0.14]

Notes: SATE is the ITT effect adjusted by the sample compliance rate in the RCT. Estimates in brackets represent 95% bootstrap confidence intervals constructed with 1,000 bootstrap samples.

Figure A5: Heterogeneity in sample and population treatment effect estimates: any ER visit. Horizontal lines represent 95% bootstrap confidence intervals constructed with 1,000 bootstrap samples.



Figure A6: Heterogeneity in population treatment effect estimates: # ER visits.



Figure A7: Heterogeneity in population treatment effect estimates: # outpatient visits.

Table A5: Distribution of MSE for compliance ensemble.

Algorithm	Mean	SE	Min.	Max.
Super learner (`SuperLearner`)	0.22	0.001	0.21	0.23
Lasso regression (`glmnet`)	0.22	0.001	0.21	0.23
Random forests (`randomForest`)	0.27	0.002	0.25	0.29
Ridge regression (`glmnet`)	0.22	0.001	0.21	0.23

Notes: MSE is 10-fold cross-validated error for super learner ensemble and candidate algorithms. R package used for implementing each algorithm in parentheses.

Table A6: Error and weights for candidate algorithms in response ensemble for RCT compliers.

Any ER visit		
Algorithm	MSE	Weight
Lasso regression (`glmnet`)	0.18	1
Random forests, $\#preds. = 1$ (`randomForest`)	0.25	0
Random forests, $\#preds. = 10$ (`randomForest`)	0.24	0
Regularized logistic regression, $\alpha = 0.25$ (`glmnet`)	0.19	0
Regularized logistic regression, $\alpha = 0.5$ (`glmnet`)	0.19	0
Regularized logistic regression, $\alpha = 0.75$ (`glmnet`)	0.19	0
Ridge regression (`glmnet`)	0.18	0
# ER visits		
Algorithm	MSE	Weight
Additive regression, degree = 3 (`gam`)	0.95	0
Additive regression, degree = 4 (`gam`)	0.95	0
Lasso regression (`glmnet`)	0.95	0.92
Random forests, $\#preds. = 1$ (`randomForest`)	0.95	0
Random forests, $\#preds. = 10$ (`randomForest`)	0.99	0.08
Regularized linear regression, $\alpha = 0.25$ (`glmnet`)	0.95	0
Regularized linear regression, $\alpha = 0.5$ (`glmnet`)	0.95	0
Regularized linear regression, $\alpha = 0.75$ (`glmnet`)	0.95	0
Ridge regression (`glmnet`)	0.18	0
# outpatient visits		
Algorithm	MSE	Weight
Additive regression, degree = 3 (`gam`)	8.40	0
Additive regression, degree = 4 (`gam`)	8.40	0
Lasso regression (`glmnet`)	8.38	0
Random forests, $\#preds. = 1$ (`randomForest`)	8.38	0
Random forests, $\#preds. = 10$ (`randomForest`)	8.79	0.08
Regularized linear regression, $\alpha = 0.25$ (`glmnet`)	8.38	0
Regularized linear regression, $\alpha = 0.5$ (`glmnet`)	8.38	0
Regularized linear regression, $\alpha = 0.75$ (`glmnet`)	8.38	0.92
Ridge regression (`glmnet`)	8.38	0

Notes: cross-validated error and weights used for each algorithm in super learner ensemble. *MSE* is the ten-fold cross-validated mean squared error for each algorithm. *Weight* is the coefficient for the Super Learner, which is estimated using non-negative least squares based on the Lawson-Hanson algorithm. R package used for implementing each algorithm in parentheses. $\#preds.$ is the number of predictors randomly sampled as candidates in each decision tree in random forests algorithm. α is a parameter that mixes L1 and L2 norms. degree is the smoothing term for smoothing splines.

Table A7: Error and weights for candidate algorithms in response ensemble for all RCT participants.

Any ER visit		
Algorithm	MSE	Weight
Lasso regression (`glmnet`)	0.18	0.96
Random forests, $\#preds. = 1$ (`randomForest`)	0.25	0
Random forests, $\#preds. = 10$ (`randomForest`)	0.24	0.04
Regularized logistic regression, $\alpha = 0.25$ (`glmnet`)	0.18	0
Regularized logistic regression, $\alpha = 0.5$ (`glmnet`)	0.18	0
Regularized logistic regression, $\alpha = 0.75$ (`glmnet`)	0.18	0
# ER visits		
Algorithm	MSE	Weight
Additive regression, degree = 3 (`gam`)	0.94	0
Additive regression, degree = 4 (`gam`)	0.94	0
Lasso regression (`glmnet`)	0.93	0.88
Random forests, $\#preds. = 1$ (`randomForest`)	0.93	0
Random forests, $\#preds. = 10$ (`randomForest`)	0.97	0.11
Regularized linear regression, $\alpha = 0.25$ (`glmnet`)	0.93	0
Regularized linear regression, $\alpha = 0.5$ (`glmnet`)	0.93	0
Regularized linear regression, $\alpha = 0.75$ (`glmnet`)	0.93	0
Ridge regression (`glmnet`)	0.93	0
# outpatient visits		
Algorithm	MSE	Weight
Additive regression, degree = 3 (`gam`)	8.42	0
Additive regression, degree = 4 (`gam`)	8.42	0
Lasso regression (`glmnet`)	8.41	0
Random forests, $\#preds. = 1$ (`randomForest`)	8.41	0.99
Random forests, $\#preds. = 10$ (`randomForest`)	8.79	0.01
Regularized linear regression, $\alpha = 0.25$ (`glmnet`)	8.41	0
Regularized linear regression, $\alpha = 0.5$ (`glmnet`)	8.41	0
Regularized linear regression, $\alpha = 0.75$ (`glmnet`)	8.41	0
Ridge regression (`glmnet`)	8.41	0

See notes to Fig.A6.



Figure 1: Causal diagram indicating the conditional independence assumptions needed to estimate the PATT-C.



Figure 2: Simulated RMSE, binned by compliance rate and percent eligible for the RCT. Darker tiles correspond to higher errors and white tiles correspond to missing simulated data.



Figure 3: Simulated RMSE of PATT-C, PATT, and SATE, according to compliance rates in the total population.